Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17099608 | 0.92 | GLS (0.53) | GLS | |
| SCHEMBL2547679 | 0.91 | NOTUM (0.37) | GLSNOTUM | |
| SCHEMBL31639401 | 0.78 | USP7 (0.43) | — | |
| SCHEMBL18836896 | 0.74 | GLS (0.40) | GLS | |
| SCHEMBL17099623 | 0.74 | GLS (0.40) | GLS | |
| SCHEMBL29740320 | 0.69 | — | — | |
| SCHEMBL154932 | 0.69 | — | — | |
| SCHEMBL17115617 | 0.67 | GLS (0.53) | GLS | |
| SCHEMBL17115650 | 0.67 | GLS (0.53) | GLS | |
| SCHEMBL17115628 | 0.67 | GLS (0.49) | GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3119199-B1 | COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS INC (US) | 2020-03-18 | — | — | EP | disclosed |
| US-10000479-B2 | Compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-10000479-B2 | Compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-10000479-B2 | Compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170137414-A1 | COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170137414-A1 | COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170137414-A1 | COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| EP-3119199-A1 | COMPOUNDS AND THEIR METHODS OF USE | Agios Pharmaceuticals, Inc. (US) | 2017-01-25 | — | — | EP | disclosed |
| WO-2015143340-A1 | COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015143340-A1 | COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2015-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137414-A1 | COMPOUNDS AND THEIR METHODS OF USE | GLS, GLS2, GLUL | GLS 1/4885NOTUM 528/4885OPRM1 4654/4885 |
| US-10000479-B2 | Compounds and their methods of use | GLS, GLS2, GLUL | GLS 1/4885NOTUM 528/4885OPRM1 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.